
    
      Part A: Part A is a randomized, double blind, placebo controlled, single ascending dose
      sequential group study evaluating the safety, tolerability, PK, and PD of a single SC dose of
      CB4211 in healthy non obese subjects.

      Part B: Part B is a randomized, double blind, placebo controlled, multiple ascending dose
      sequential group study evaluating the safety, tolerability, PK, and PD of once daily SC doses
      of CB4211 over 7 days in healthy non obese subjects.

      Part C: Part C is a randomized, double blind, placebo controlled, multiple dose, parallel
      group study evaluating the safety, tolerability, PK, and PD of once daily SC doses of CB4211
      over 28 days in subjects with NAFLD.
    
  